Trialect

+ More Filters

Reset Filters

Specialty

Funding Organization

Funding Type

Eligible Country

Deadline

From

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Limited Competition: Small Grant Program for NHLBI K01/K08/K23/K25 Recipients (R03 Clinical Trial Optional)

National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to solicit current or recently completed NHLBI K01, K08, K23, and K25 recipients for small grant support to expand their current research objectives or to branch out to a new study that resulted from the research conducted under the K award. Active NHLBI K01, K08, K23, and K25 recipients may apply for R03 support after the notice of award (NoA) for their first type-5 K awards has been issued. Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible to apply for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date. This FOA is intended to enhance the capability of NHLBI K01, K08, K23, and K25 recipients to conduct research as they complete their transition to fully independent investigator status.

This R03 program is intended to support research projects that can be carried out and completed within a short period of time (no more than two years) with limited resources and that may generate preliminary data to support a subsequent R01-equivalent application. These studies include, but are not limited to, pilot or feasibility studies; proof of concept studies; secondary analysis of existing data; small, self-contained research projects; development of new research methodologies or technologies, or development of novel experimental models. A minimum of 40% protected overall research effort, not necessarily limited to the proposed R03 project, is required from applicants. For current and previous K23 recipients, research proposed in the R03 application may or may not include patient-oriented research.

Deadlines:

Application Due Date(s): Feb. 14, 2023; June 13, 2023; Oct 13, 2023; Feb 13, 2024; June 13, 2024; Oct 17, 2024; Feb 13, 2025; June 13, 2025; Oct 13, 2025
AIDS Application Due Date(s): Jan. 7, May 7, Sep. 7

RFA-HL-24-005 Expiration Date January 08, 2026

Specialties

Medical

Medical - Clinical Science

Medical - Basic Science

Medical - Translational

Eligibility Requirements

Only the following NHLBI K recipients are eligible to apply for this funding opportunity:

Current NHLBI-supported K01, K08, K23, and K25 recipients become eligible to apply for this R03 after the notice of award (NoA) for their first type-5 K award has been issued. The R03 award for the second year does not require concurrent K-support.
Recently completed NHLBI K01, K08, K23, and K25 recipients - defined as such if their NHLBI K award project period end date is prior to the intended start date of the R03. The earliest possible R03 start date must fall within 2 years of the applicant’s prior NHLBI K award Project Period end date.
Recently completed NHLBI K01, K08, K23, and K25 recipients are eligible for resubmission (an A1 application) for the R03 if the earliest possible R03 start date falls within 2 years of their prior NHLBI K award Project Period end date.

A minimum of 40% protected overall research effort is required from applicants during the R03 award period and can be met through a combination of effort on the proposed R03 and other research projects, regardless of funding source (see Instructions for Institutional Commitment to Applicant Letter of Support in Section IV for additional details). This minimal protected research effort should be clearly indicated in the Institutional Commitment Letter and submitted as part of grant application, but will be accepted as a Just-In-Time submission. NHLBI K01, K08, K23, or K25 recipients who have already successfully competed for an R01, or other substantial NIH independent research award are ineligible for R03 program. See Definition of New Investigator for the definition of “substantial NIH independent research award."

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity